Heart failure & cardiomyopathies
The Favourable Alliance Between CardioMEMS and Levosimendan in Patients with Advanced Heart Failure
Authors' conclusion
This innovative strategy prevents unplanned access to the hospital and contributes to the efficient use of healthcare facilities, human resources, and costs.
Study context
- Population
- Patients with heart failure (HF) implanted with CardioMEMS, daily remote monitored to tailor home therapy and/or levosimendan infusions
- Participants
- 7 patients
- Exposure
- After vs before CardioMEMS implantation
- Outcome
- Hospitalizations
Methodological detailsbefore–after comparison
- Before–after comparison
Main finding
As reported in the abstract
Reduction in total number of hospitalizations
50%
Reduction in number of days in hospital
68.7%
Observational data: associations, not effects.
Further findings
| Outcome | Post-CardioMEMS | Pre-CardioMEMS | P value |
|---|---|---|---|
| Quality of life (EQ-5D) · 1 year post | 84.29 ± 19.02 | 58.57 ± 10.29 | P = 0.008 |
| Systolic pulmonary artery pressure (echocardiography) | 35.14 ± 9.34 | 47.86 ± 8.67 | P = 0.022 |
| E/e' | 12.58 ± 3.53 | 19.33 ± 5.04 | P = 0.023 |
Interleukin-6 · 6 months
- Elevated at enrolment in all patients; statistically significant reduction after 6 months
- P = 0.0211
Costs
- Net saving per patient over entire observation period, incl. CardioMEMS cost (average)
- €1580
- Net saving per patient, 12 months after vs 12 months before implant
- €860
Levosimendan infusions (ad hoc analysis)
- Days of hospital avoidance
- 315
- Saving for the seven patients
- €205 158
Original publication
The Favourable Alliance Between CardioMEMS and Levosimendan in Patients with Advanced Heart Failure. ESC Heart Fail. Published 18 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →